摘要
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing > two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.
学科与关键词
- Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trialCheng, Ying*; Wang, Qiming; Li, Kai; Shi, Jianhua; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingCancer Medicine, 2022, 11(4): 1081-1087.被引 9
- The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancerWang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
- Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III TrialCheng, Y.; Yang, R.; Chen, J.; Zhang, W.; Xie, C.; Hu, Q.; Zhou, N.; Huang, C.; Wei, S.; Sun, H.; Li, X.; Yu, Y.; Lai, J.; Yang, H.; Fang, H.; Chen, H.; Zhang, P.; Gu, K.; Wang, Q.; Shi, J.; Yi, T.; Xu, X.; Ye, X.; Wang, D.; Xie, C.; Liu, C.; Zheng, Y.; Lin, D.; Zhuang, W.; Lu, P.; Yu, G.; Li, J.; Gu, Y.; Li, B.; Wu, R.; Jiang, O.; Wang, Z.; Wu, G.; Lin, H.; Zhong, D.; Xu, Y.; Shu, Y.; Wu, D.; Chen, X.; Wang, J.; Wang, M.
